Histologically confirmed primary breast cancer
Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy
=19 years of age
Able to provide verbal consent

NCT02816164_inc_T1
Condition
primary breast cancer
NCT02816164_inc_T2
Qualifier
Histologically confirmed
NCT02816164_inc_T3
Procedure
Histologically
NCT02816164_inc_T4
Drug
docetaxel
NCT02816164_inc_T5
Mood
Planned to start
NCT02816164_inc_T6
Procedure
FEC-D
NCT02816164_inc_T7
Procedure
AC-D
NCT02816164_inc_T8
Multiplier
first cycle of
NCT02816164_inc_T9
Procedure
dose-dense AC-T
NCT02816164_inc_T10
Procedure
TC
NCT02816164_inc_T11
Procedure
FEC-D
NCT02816164_inc_T12
Procedure
TAC chemotherapy
NCT02816164_inc_T13
Scope
FEC-D or AC-D
NCT02816164_inc_T14
Scope
irst cycle of; ocetaxel
NCT02816164_inc_T15
Person
age
NCT02816164_inc_T16
Value
=19 years